Artiva Biotherapeutics (ARTV) Current Leases (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Current Leases data on file, last reported at $3.0 million in Q1 2026.

• On a quarterly basis, Current Leases fell 15.86% year-over-year to $3.0 million in Q1 2026; TTM through Mar 2026 was $3.0 million, a 15.86% decrease from a year earlier, with the FY2025 full-year figure at $3.0 million, up 2371.31% from the prior year.
• Current Leases for Q1 2026 stood at $3.0 million, roughly flat from $3.0 million in the prior quarter.
• Over the last five years, Current Leases for ARTV reached as high as $3.7 million in Q2 2024 and fell as low as $75000.0 in Q3 2025.
• Historically, Current Leases has averaged $2.3 million across 4 years, with a median of $3.0 million in 2026.
• On a YoY basis, Current Leases climbed as much as 2371.31% in 2025 and fell as far as 97.92% in 2025.
• Year by year, Current Leases stood at $3.6 million in 2023, then tumbled by 96.61% to $122000.0 in 2024, then surged by 2371.31% to $3.0 million in 2025, then rose by 0.3% to $3.0 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $3.0 million in Q1 2026, $3.0 million in Q4 2025, and $75000.0 in Q3 2025.